Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016

Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016
Published Jun 30, 2016
60 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016, provides in depth analysis on Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging player

  
Source:
Document ID
GMDHC0240TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Overview71
Therapeutics Development84
  Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Stage of Development81
  Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Therapy Area91
  Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Indication102
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Companies142
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Products under Development by Universities/Institutes162
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Therapeutics Assessment185
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type221
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Companies Involved in Therapeutics Development234
  Advenchen Laboratories, LLC231
  Athenex, Inc.241
  Basilea Pharmaceutica AG251
  Pfizer Inc.261
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Drug Profiles2720
  apatinib Drug Profile273
  bosutinib Drug Profile305
  CCT-196969 Drug Profile351
  CCT-241161 Drug Profile361
  eCF-506 Drug Profile371
  KX-01 Drug Profile382
  KX-02 Drug Profile402
  PP-1 Drug Profile421
  Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology Drug Profile431
  Small molecules to Inhibit Src Kinase for Oncology Drug Profile441
  Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer Drug Profile451
  UM-164 Drug Profile461
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Dormant Projects471
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Discontinued Products481
Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) Featured News &Press Releases4910
  Jun 08, 2016: New compound shows potential for triple-negative breast cancer491
  May 23, 2016: Breast cancer drug discovery offers hope of new treatments501
  Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia501
  Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic511
  Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study511
  Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study521
  Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014531
  Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia531
  Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)541
  Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial551
  Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia551
  Dec 04, 2013: Kinex Pharmaceuticals Announced that the U.S. Food and Drug Administration has Granted Orphan Drug Status to KX02 for the Treatment of Gliomas561
  Jul 16, 2013: NICE consults on a new treatment for chronic myeloid leukaemia561
  Jun 04, 2013: Kinex Pharma Receives IND Approval From FDA For KX02 Clinical Trials In Brain Tumor Patients571
  Mar 28, 2013: Pfizer s Bosulif Receives Conditional Marketing Authorization From European Commission581
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-CSK-C-Src-Kinase-or-Protein-Tyrosine-Kinase-CYL-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-16117>
  
APA:
Global Markets Direct - Market Research. (2016). Tyrosine-Protein Kinase CSK (C-Src Kinase or Protein-Tyrosine Kinase CYL or EC 2.7.10.2) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-CSK-C-Src-Kinase-or-Protein-Tyrosine-Kinase-CYL-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-16117>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.